论文部分内容阅读
只用2年,痰热清销售额呈十倍速度增长,跃升为呼吸系统中成药品牌排行冠军。其成功的秘密在哪里?2006年11月,SFDA南方医药经济研究所广州标点公司发布“呼吸系统用中成药”统计结果:痰热清注射液上市三年,累计销售1000万支,销售额2004年1700万元,2005年8000万元,今年稳超2亿元。当下,处方药市场政策趋严,企业面临营销转型,新品上市难度增大。在此背景下,痰热清注射液“整合学术营销”成功,就更多了几重借鉴意义。
Only 2 years, sales of sputum heat ten times the rate of growth, jumped to respiratory system proprietary brand champion. In November 2006, SFDA Institute of Southern Medical Economics Guangzhou punctuation company released the “Respiratory system with proprietary Chinese medicines” statistical results: Tanreqing injection three years, the cumulative sales of 10 million, sales in 2004 Year 17 million yuan, 80 million yuan in 2005, steady over 200 million yuan this year. At present, prescription drug market policies tightened, companies face marketing transformation, new products more difficult to market. In this context, Tanreqing injection “integrated academic marketing” success, even more for a few referential significance.